Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?

被引:318
作者
Zimmerman, M
Mattia, JI
Posternak, MA
机构
[1] Bayside Med Ctr, Providence, RI 02905 USA
[2] Brown Univ, Rhode Isl Hosp, Sch Med, Dept Psychiat & Human Behav, Providence, RI 02903 USA
关键词
D O I
10.1176/appi.ajp.159.3.469
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: The methods used to evaluate the efficacy of antidepressants differ from treatment for depression in routine clinical practice. The rigorous inclusion/exclusion criteria used to select subjects for participation in efficacy studies potentially limit the generalizability of these trials' results. It is unknown how much impact these criteria have on the representativeness of subjects in efficacy trials. This study estimated the proportion of depressed patients treated in routine clinical practice who would meet standard inclusion/exclusion criteria for an efficacy trial. Method: A total of 803 individuals, aged 16-65 years, who were seen at intake at an outpatient practice underwent a thorough diagnostic evaluation, including the administration of semistructured diagnostic interviews; 346 patients had current major depression. Common inclusion/exclusion criteria used in efficacy studies of antidepressants were applied to the depressed patients to determine how many would have qualified for an efficacy trial. Results: Approximately one-sixth of the 346 depressed patients would have been excluded from an efficacy trial because they had a bipolar or psychotic subtype of depression. The presence of a comorbid anxiety or substance use disorder, insufficient severity of depressive symptoms, or current suicidal ideation would have excluded 86.0% (N=252) of the remaining 293 outpatients with nonpsychotic unipolar major depressive disorder from an antidepressant efficacy trial. Conclusions: Subjects treated in antidepressant trials represent a minority of patients treated for major depression in routine clinical practice. These results show that antidepressant efficacy trials tend to evaluate a subset of depressed individuals with a specific clinical profile.
引用
收藏
页码:469 / 473
页数:5
相关论文
共 26 条
[1]   CONSENSUS CONFERENCE ON THE METHODOLOGY OF CLINICAL-TRIALS OF ANTIDEPRESSANTS, ZURICH, MARCH 1988 - REPORT OF THE CONSENSUS COMMITTEE [J].
ANGST, J ;
BECH, P ;
BOYER, P ;
BRUINVELS, J ;
ENGEL, R ;
HELMCHEN, H ;
HIPPIUS, H ;
LINGJAERDE, O ;
RACAGNI, G ;
SALETU, B ;
SEDVALL, G ;
SILVERSTONE, JT ;
STEFANIS, CN ;
STOLL, K ;
WOGGON, B .
PHARMACOPSYCHIATRY, 1989, 22 (01) :3-7
[2]   Treatment utilization by patients with personality disorders [J].
Bender, DS ;
Dolan, RT ;
Skodol, AE ;
Sanislow, CA ;
Dyck, IR ;
McGlashan, TH ;
Shea, MT ;
Zanarini, MC ;
Oldham, JM ;
Gunderson, JG .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (02) :295-302
[3]   SYMPTOMATIC VOLUNTEERS - ANOTHER PATIENT DIMENSION FOR CLINICAL TRIALS [J].
BRAUZER, B ;
GOLDSTEIN, BJ .
JOURNAL OF CLINICAL PHARMACOLOGY, 1973, 13 (2-3) :89-98
[4]   SOLICITATION OF ELDERLY DEPRESSIVES FOR TREATMENT OUTCOME RESEARCH - A COMPARISON OF REFERRAL SOURCES [J].
BRECKENRIDGE, JS ;
ZEISS, AM ;
BRECKENRIDGE, JN ;
GALLAGHER, D ;
THOMPSON, LW .
JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 1985, 53 (04) :552-554
[5]  
COHENCOLE SA, 1993, DEPRESSION, V1, P181, DOI DOI 10.1002/DEPR.3050010402
[6]   SYMPTOMATIC VOLUNTEERS IN MULTICENTER DRUG TRIALS [J].
COVI, L ;
LIPMAN, RS ;
MCNAIR, DM ;
CZERLINSKY, T .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY, 1979, 3 (5-6) :521-533
[7]   A COMPARISON OF PAROXETINE, IMIPRAMINE AND PLACEBO IN DEPRESSED OUT-PATIENTS [J].
DUNBAR, GC ;
COHN, JB ;
FABRE, LF ;
FEIGHNER, JP ;
FIEVE, RR ;
MENDELS, J ;
SHRIVASTAVA, RK .
BRITISH JOURNAL OF PSYCHIATRY, 1991, 159 :394-398
[8]  
DUNLOP SR, 1990, PSYCHOPHARMACOL BULL, V26, P173
[9]  
ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837
[10]  
ENDICOTT J, 1981, ARCH GEN PSYCHIAT, V38, P98